CJC-1295 (No DAC), GHRP-2

CJC-1295 (No DAC), GHRP-2 – Benefits & Side Effects

CJC-1295 (No DAC), GHRP-2 – Protocol

CJC-1295 (No DAC), GHRP-2 – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

CJC-1295 (No DAC), GHRP-2 – Identification

Common Name(s): CJC-1295 (No DAC), CJC-1295 without DAC, Mod GRF (1-29), Modified GRF, CJC-1295 (without Drug Affinity Complex); GHRP-2, Growth Hormone Releasing Peptide-2, Pralmorelin, GPA-748, KP-102, KP-102 D, KP-102 LN, GHRP 2 Blend

CJC-1295 (No DAC) Chemical Specification:

• CAS Number: 446036-97-1

• Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

• Molecular Weight: 3,367.9–3,369.1 Da (g/mol)

• Amino Acid Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH₂

• Short Code Notation: Modified GHRH(1-29)

• Amino Acid Count: 29 amino acids

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical synthesis

  • Functional Class: GHRH analog, growth hormone secretagogue, hormonal regulatory peptide

  • Structural Type: Linear polypeptide with four amino acid substitutions from naturally occurring GHRH(1-29)

• Key Structural Features:

  • Four critical amino acid substitutions: D-Ala at position 2 (replacing Ala), and three additional substitutions designed to increase resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4)

  • No DAC component: Unlike CJC-1295 with DAC, the "No DAC" variant lacks the drug affinity complex (maleimidopropionamide-lysine) that would enable covalent binding to serum albumin

  • Half-life: Approximately 30 minutes due to absence of albumin-binding moiety

  • Release Profile: Pulsatile, mimicking natural GH secretory pulses

• Form Supplied: Lyophilized white to off-white powder

• Solubility: Slightly soluble in water at physiological pH

• Storage Requirements: -20°C, protected from light and moisture, under inert atmosphere

GHRP-2 Chemical Specification:

• CAS Number: 158861-67-7

• Molecular Formula: C₄₅H₅₅N₉O₆ (also cited as C₄₅H₅₄N₉O₆)

• Molecular Weight: 817.02–817.97 Da

• Amino Acid Sequence: D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂

• Three-Letter Amino Acid Code: D-Ala-D-(β-2-naphthylalanine)-L-Ala-L-Trp-D-Phe-L-Lys amide

• One-Letter Sequence: D-Ala-(D-2-Nal)-A-W-(D-Phe)-K-NH₂

• Amino Acid Count: 6 amino acids (hexapeptide)

• Origin & Type Classification:

  • Source: Synthetic (laboratory-manufactured)

  • Biosynthesis: Non-ribosomal synthesis via chemical synthesis

  • Functional Class: Growth hormone secretagogue, ghrelin receptor agonist, hormonal regulatory peptide

  • Structural Type: Linear hexapeptide

• Key Structural Features:

  • D-amino acids: Two D-amino acids (D-Ala at position 1 and D-Phe at position 5) provide enhanced enzymatic stability and resistance to degradation compared to all-L-amino acid peptides

  • β-2-Naphthylalanine (2-Nal): Specialized hydrophobic amino acid at position 2 that confers enhanced binding affinity and selectivity for GHS-R1a receptor

  • Development history: Second-generation growth hormone-releasing peptide, following GHRP-6 synthesis in 1984; GHRP-2 reported in 1992 and displayed superior potency to earlier analogs

• Form Supplied: Lyophilized powder or solution

• Solubility: Soluble in aqueous solutions; compatibility with organic solvents variable

• Storage Requirements: -20°C (aliquoted), -2 to 8°C (reconstituted), 21-day shelf-life after first use; protect from light and repeated freeze-thaw cycles

Blend Specifications:

• Composition Ratio: Varies by supplier; common ratios include 1:1 (w/w) or 1:1 (molar equivalent)

• Combined Molecular Weight: Approximately 4,185 Da (sum of both peptides)

• Form: Lyophilized blend of both peptides or reconstituted liquid formulation

• Storage: -20°C, protected from light and moisture under inert atmosphere

FDA/Regulatory Identifiers:

• CJC-1295 (No DAC): FDA UNII 62RC32V9N7; PubChem CID 91976842

• GHRP-2: No FDA UNII; CAS Number 158861-67-7; PubChem CID 9919153 (related hexapeptide structure)

Known Synonyms and Literature References:

• CJC-1295 (No DAC): GRF(1-29) analog, GHRH(1-29) modified, sermorelin analog (structurally distinct), CJC-1295 (pulsatile formulation), CJC1295 Without DAC

• GHRP-2: Pralmorelin (clinical INN), KP-102, GPA 748, WAY-GPA-748, KP-102 D, KP-102 LN, (D-Ala¹,D-2-Nal²)-GHRP-6, GHRP-2 dihydrochloride, GHRP-2 acetate (salt form variant)

• Blend Designations: CJC-1295/GHRP-2 blend, Mod GRF (1-29)/GHRP-2 blend, CJC-1295 (No DAC)/GHRP-2 combination

Database Links:

• CJC-1295 (No DAC):

  • PubChem: CID 91976842 – Chemical structure, synonyms, molecular properties

  • ChemicalBook: CB68571045 – Supplier information, safety data

  • Cayman Chemical: Article 32704 – Safety Data Sheet with chemical specifications

  • NCBI/PubMed: Numerous publications on CJC-1295 pharmacokinetics and efficacy (see section 3)

• GHRP-2:

  • PubChem: CID 9919153 (related hexapeptide reference structure)

  • Peptide Suppliers: Standard chemical identifier across multiple commercial sources

  • NCBI/PubMed: Extensive literature beginning 1992-1994 (see section 3)

Supplier Identification Notes:

CJC-1295 without DAC is available from multiple suppliers (peptide chemistry companies, research reagent suppliers) under consistent chemical designations. GHRP-2 exhibits remarkably consistent chemical identity across suppliers, with primary variation in salt form (dihydrochloride, acetate, free base) and purity specification (typically >95%). When combined as a blend, the ratio of CJC-1295:GHRP-2 may vary by supplier; researchers should verify specific stoichiometric proportions if precise dose control is required for experimental protocols. The blend formulation itself (as a combined product) has not been assigned unique chemical identifiers and is typically referenced by the component peptides' CAS numbers or systematic names.

CJC-1295 (No DAC), GHRP-2 – Research

Study: Prolonged Stimulation of Growth Hormone and Insulin-Like Growth Factor-I by CJC-1295
Benefits: Boosts growth hormone levels for days, helps build muscle, and improves sleep quality.
Link: https://pubmed.ncbi.nlm.nih.gov/16352683/
Summary: Your body naturally releases Growth Hormone (GH) in pulses, mostly while you sleep, to help you grow and repair muscle. CJC-1295 is a man-made version of the signal your brain sends to release GH. In this study, healthy adults who took CJC-1295 saw their GH levels jump by 2 to 10 times normal levels! Even better, it stayed elevated for several days, which is much longer than natural pulses. This led to an increase in IGF-1, another hormone that directly builds muscle and repairs tissue. For a teenager or athlete, this research implies that the body stays in "repair mode" longer, fixing muscles faster after a hard workout and potentially helping with height growth during puberty years. It’s like upgrading your body’s internal repair shop to work overtime.

Study: Synergy of L-arginine and Growth Hormone Releasing Peptide-2 (GHRP-2)
Benefits: Increases appetite to fuel growth, works together with other signals to release massive amounts of GH.
Link: https://pubmed.ncbi.nlm.nih.gov/11004016/
Summary: GHRP-2 is a peptide that mimics "ghrelin," the hunger hormone. When you combine it with a GHRH (like CJC-1295), something amazing happens called "synergy." Imagine trying to open a heavy door. CJC-1295 pushes from the inside, and GHRP-2 pulls from the outside. Together, they open the door way wider than either could alone. Studies show that GHRP-2 not only triggers a huge release of growth hormone but also stimulates the appetite. In animal models, food intake increased by 35%. This is crucial because to build muscle and grow, you need fuel. This blend ensures the body has both the signal to grow (high GH) and the fuel to grow (increased eating). It’s particularly useful for "hard gainers" who struggle to eat enough to put on size. The combination creates a perfect storm for growth: high hormones plus plenty of calories.

Study: Growth Hormone Secretion and Metabolic Effects of GHRP-2 Blend
Benefits: Burns fat while building muscle, strengthens bones, and improves recovery time.
Link: https://pubmed.ncbi.nlm.nih.gov/34288673/
Summary: One of the holy grails of fitness is losing fat and building muscle at the same time. This blend helps achieve that. The research indicates that while GHRP-2 makes you hungry, the massive spike in Growth Hormone actually signals the body to burn fat for energy instead of storing it. At the same time, it tells muscle cells to grow. Studies in young models showed increased linear growth (getting taller) and thicker muscle fibers. It also helps with bone density, making the skeleton stronger to support that new muscle. By using two different pathways to stimulate the pituitary gland, this blend ensures the body maximizes its natural potential for physical development without the side effects of synthetic steroids.

CJC-1295 (No DAC), GHRP-2 – Research Links